Mediterr J Rheumatol 2024;35(Suppl 1):27-36
Selective JAK-Inhibitors in Spondyloarthritis
Authors Information
  1. Joint Academic Rheumatology Program, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
  2. School of Infection and Immunity, University of Glasgow, United Kingdom

As our research interest and knowledge increases in the field of Spondyloarthritis, new aspects also emerge as regards to their therapeutic approach. JAK inhibitors (JAKi) are a relatively new treatment option, aiming molecules in the JAK-STAT pathway, which has a leading role in the pathophysiology of both Psoriatic Arthritis and Axial Spondyloarthritis. JAKi exhibit different selectivity towards the four different members of the JAK family (namely JAK1, JAK2, JAK3, and TYK2), possibly reflecting different efficacy and safety profile. Although knowledge is more consolidated for rheumatoid arthritis in which JAKi are being used for more than 10 years, data are still accumulating for PsA/SpA. In this review we aim to present and assess current knowledge about the efficacy of JAKi (with a focus on selective JAKi) in the treatment of patients with SpA and evaluate their safety profile as some concerns may arise around this therapeutic option.

Cite this article as: Vassilakis KD, Magiouf K, Siebert S, Fragoulis GE. Selective JAK-Inhibitors in Spondyloarthritis. Mediterr J Rheumatol 2024;35(Suppl 1):27-36.

Article Submitted: 31 Oct 2023; Article Accepted: 16 Nov 2023; Available Online: 30 Mar 2024

This work is licensed under a Creative Commons Attribution 4.0 International License.

©2024 The Author(s).